Brain Tumour Group,Breast Cancer Group,Gastrointestinal Tract Cancer Group,Genito-Urinary Cancers Group,Melanoma Group,News,Quality of Life Group,Radiation Oncology Group,Soft Tissue and Bone Sarcoma Group,Uncategorized
Abstracts accepted for the 2010 ASCO Annual Meeting
26 May 2010
Twenty EORTC abstracts have been accepted for presentation at the 2010 ASCO Annual meeting to be held 4-8 June in Chicago, Illinois. A listing of these abstracts is given below.
Oral Abstract Session
EORTC Genito-Urinary Tract Cancer Group
Abstract ID LBA4519
Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): phase III results of EORTC study 30986. M. De Santis, J. Bellmunt, G. Mead, J.M. Kerst, M. Leahy, G. Daugaard, T. Gil, P. Maroto, S. Marreaud, and R. Sylvester.
EORTC Melanoma Group
Abstract ID 50930
Randomized phase III trial comparing post-operative adjuvant ganglioside GM2-KLH/QS-21 vaccination vs observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. A. M. Eggermont, S. Suciu, P. Rutkowski, J. Marsden, A. Testori, P. Corrie, S. Aamdal, P. A. Ascierto, P. Patel, and A. Spatz.
EORTC Genito-Urinary Tract Cancer Group
Abstract ID 4512
A randomized phase III study comparing standard dose BEP with sequential high-dose Cisplatin, Etoposide, Ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC). An intergroup study of EORTC, GTCSG, and Gruppo Germinal (EORTC 30974). G. Daugaard, I. Skoneczna, N. Aas, R. de Wit, M. De Santis, H. Dumez, S. Marreaud, L. Collette, C. Bokemeyer, and H.J. Schmoll.
EORTC Gastrointestinal Tract Cancer Group
Abstract ID 3526
Final results of the EORTC Intergroup Randomized study 40004 (CLOCC) evaluating the benefit of Radiofrequency Ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). T. Ruers, C. Punt, F. van Coevorden, J.P. Pierie, I. Borel Rinkes, J. Ledermann, G. J. Poston, W. Bechstein, M. Lentz, M. Mauer, and B. Nordlinger.
EORTC Breast Cancer Group
Abstract ID LBA503
Phase III breast cancer trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict for sensitivity to a taxane versus non taxane primary chemotherapy regimen: final analysis. Hervé Bonnefoi, Jan Bogaerts, Martine Piccart, Louis Mauriac, Pierre Fumoleau, Jacek Jassem, Véronique Becette, David Cameron, Jonas Bergh and Richard Iggo.
Poster Discussion Session
EORTC Quality of Life Group
Abstract ID 9146
Health related quality of life and clinical data comprise a valid prognostic tool to aid in survival prediction in a subgroup of metastatic cancer patients. C. Quinten, F. Martinelli, J. Vercauteren, E. Greimel, B. Reeve, C. Cleeland, M. Taphoorn, J. Weis, J. Schmucker-von Koch, and A. Bottomley.
EORTC Soft Tissue and Bone Sarcoma Group
Abstract ID 10074
First line chemotherapy for malignant peripheral nerve sheath tumour (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC soft tissue and bone sarcoma group (STBSG) study. J. R. Kroep, M. Ouali, H. Gelderblom, A. Le Cesne, T. J. A. Dekker, M. M. Van Glabbeke, P. Hohenberger, and P. C. W. Hogendoorn.
EORTC Lung Cancer Group
Abstract ID 7518
A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021- ILCP 01/03). R. M. Gaafar, V. Surmont, G. Scagliotti, R. Van Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, and J. P. Van Meerbeeck.
EORTC Brain Tumor and Radiation Oncology Groups
Abstract ID 9306
Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole brain radiotherapy versus observation after radio surgery or surgical resection of 1-3 cerebral metastases of solid tumors. R. Soffietti, R. P. Mueller, M. U. Abacioglu, S. Villa, F. Fauchon, B. Baumert, L. Fariselli, G. Tridello, M. Kocher, and A. Bottomley.
EORTC Soft Tissue and Bone Sarcoma Group
Abstract ID 10040
Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts); An EORTC-STBSG study. S. Sleijfer, M. M. Van Glabbeke, C. Lamers, H. Burger, J. Y. Blay, A. L. Cesne, M. R. Scurr, A. N. Bartlett-Pandite, S. Marreaud, and P. Hohenberger.
EORTC Soft Tissue and Bone Sarcoma Group
Abstract ID 10051
Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. P. Biron, P.A. Cassier, E. Fumagalli, A. Blesius, M. Debiec-Rychter, A. Adenis, J. Verweij, P. Hohenberger, J.Y. Blay, and P.G. Casali.
EORTC Soft Tissue and Bone Sarcoma Group
Abstract ID 10031
Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC 62052). P. Schoffski, I. L. Ray-Coquard, A. Cioffi, N. Bin Bui, S. Bauer, J. T. Hartmann, R. Sciot, J. Wanders, D. Druyts, and P. Hohenberger.
EORTC Soft Tissue and Bone Sarcoma Group
Abstract ID 10037
Brostallicin versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. H. Gelderblom, J.Y. Blay, B. M. Seddon, M. Leahy, I.L. Ray-Coquard, A. De brauwer, E. Veyt, S.D. Weitman, P.C.W. Hogendoorn, and P. Hohenberger.
EORTC Breast Cancer Group
Abstract ID TPS116
LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neo-adjuvant therapy of HER2 positive breast cancer: EORTC 10054 trial. D.A. Cameron, S. Marreaud, K. Zaman, A. Bodmer, J.Y. Pierga, E. Brain, C. Veyret, J.M. Bartlett, J. Bogaerts, and H.R. Bonnefoi.
EORTC Gastrointestinal Tract Cancer Group
Abstract ID 3591
Lessons from PETACC 2 – no prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy. D.E. Aust, M.P. Lutz, M. Mauer, I. Popov, G.B. Baretton, L. Bedenne, A. Carrato, and C.H. Köhne.
General Poster Session
EORTC Quality of Life Group
Abstract ID 9075
The association between clinical, socio-demographic and logistic-administrative factors and adherence to completing health-related quality of life questionnaires. J. Vercauteren, J. Maringwa, C. Coens, C. Quinten, C. Gotay, J. Ringash, M. King, D. Osoba, H. Flechtner and A. Bottomley on behalf of the EORTC.
EORTC Lung Cancer Group
Abstract ID 7052
Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). M.E.R O’Brien, J. Jassem, P. Lorigan, L. Bosquee, E. Marshall, F. Bustin, J. Stigt, A.C. Dingemans, B. Hasan, and J.P. Van Meerbeeck.
EORTC Gastrointestinal Tract Cancer Group
Abstract ID TPS205
Lapatinib in Combination with ECF/X in EGFR1 or HER2 Overexpressing First-Line Metastatic Gastric Cancer (GC): A Phase II Randomized Placebo Controlled Trial (EORTC 40071). Arnaud Roth, Markus Moehler, Murielle Mauer, A Schad, Matthias Karrasch, Michel Praet, Michael Lim, Ash Das-Gupta, and Manfred P. Lutz.
EORTC Gastrointestinal Tract Cancer Group
Abstract ID 3544
Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). H. Sorbye, M. Mauer, T. Gruenberger, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, J. N. Primrose, E. T. Walpole, B. Nordlinger.
Publication Only
EORTC New Drug Development Group
Abstract ID 53018
Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: a dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) EORTC study. H.W.M. van Laarhoven, I.M.E. Desar, J.J.A. van Asten, W. Fiedler, S. Marreaud, J.N.H. Timmer-Bonte, E.G.W. ter Voert, A. Lambiase, A. Heerschap, and C.M.L. van Herpen.
Stéphanie Vandergooten
John Bean
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023